WeGovy (semaglutide) is a powerful medication that has garnered attention for its FDA approval for weight loss. Interestingly, it shares the same active ingredient as Ozempic - both medications are semaglutide and work similarly. Manufactured by Novo Nordisk, WeGovy and Ozempic have different brand names and slightly varied dosing schedules. The crucial distinction between the two lies in their FDA-approved uses: while Ozempic is approved for diabetes, WeGovy has full FDA approval for chronic weight management.

Approved in June 2021, WeGovy is suitable for patients with a body mass index (BMI) of 27 kg/m2 or greater and at least one weight-related condition, such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved for patients with a BMI of 30 kg/m2 or greater. Like Ozempic, WeGovy functions as a GLP-1 receptor agonist, regulating blood sugar levels and promoting a feeling of fullness between meals, which contributes to weight loss. Additionally, it helps suppress excessive sugar production in the liver.

WeGovy, administered through a weekly injection similar to an EpiPen, is typically started at a dose of 0.25 mg and gradually increased to 2.4 mg over time. Although GLP-1 receptor agonists have been used since 2005 to treat diabetes, they have evolved from requiring twice-daily injections to the current once-weekly self-injections.

While WeGovy offers promising results, it is essential to be aware of its potential side effects. Common gastrointestinal side effects include nausea, constipation, upset stomach, diarrhea, and vomiting. It is crucial to consult your healthcare provider to determine if WeGovy is the right choice for you. Additionally, WeGovy should be used under medical supervision to avoid potential side effects, and it should be noted that the medication has not been studied for use during pregnancy. Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and thyroid tumors, including cancer.

Is Wegovy the same as Ozempic?

Ozempic and Wegovy are both medications containing the active ingredient semaglutide, working in an identical manner. However, Wegovy possesses a higher maximum dosage. Although these medications share the same active component, they are marketed under distinct brand names and feature slightly different dosing schedules. It is important to note that both Ozempic and Wegovy are produced by Novo Nordisk.

What is the Difference between Ozempic and Wegovy?

- Active Ingredient: Ozempic and Wegovy both contain semaglutide as their active ingredient.

- Maximum Dosage: Wegovy has a higher maximum dosage compared to Ozempic.

- Brand Names: Ozempic and Wegovy are marketed under different brand names, despite sharing the same active ingredient.

- Dosing Schedule: The two medications have slightly different dosing schedules.

- Indications: Ozempic is primarily prescribed for type 2 diabetes management, while Wegovy is approved for chronic weight management in adults.

- Manufacturer: Both drugs are produced by the same pharmaceutical company, Novo Nordisk.

Ozempic, which is also semaglutide, is a prescription medication developed by Novo Nordisk for managing type 2 diabetes in conjunction with diet and exercise. It aids in blood sugar control and lowers the risk of severe cardiovascular events, such as heart attacks or strokes. However, it is important to note that Ozempic is not intended for type 1 diabetes treatment and is not insulin.

The FDA has approved Ozempic for type 2 diabetes treatment and for preventing severe cardiovascular events in patients with type 2 diabetes and cardiovascular disease. Furthermore, Ozempic is sometimes prescribed off-label for weight loss in overweight individuals to improve health outcomes like high blood pressure, as explained by Jamie Alan, PharmD, Ph.D., an associate professor of pharmacology at Michigan State University. High blood pressure, or hypertension, is more prevalent in overweight individuals.

Kunal Shah, MD, an assistant professor of endocrinology at Rutgers University, states that the ideal candidate for Ozempic is someone who needs to lose weight, has diabetes, and requires a reduced risk of cardiovascular complications. Ozempic has proven to be effective in reducing these risks.

Ozempic works by enhancing blood sugar levels and suppressing appetite. It also helps prevent the liver from producing excessive sugar. This medication belongs to a class of drugs called glucagon-like peptide 1 (GLP-1) receptor agonists.

Alan explains that GLP-1, also known as an incretin, has complex actions on the body. Its primary function is to increase insulin and insulin sensitivity, which is how it treats diabetes. A secondary mechanism promotes satiety or fullness, contributing to weight loss. Ozempic slows down the digestive system, making individuals feel fuller for longer periods. It has also been found to reduce sugar cravings.

Ozempic is administered via injection using a traditional insulin pen-type device, as described by Andrew Kraftson, MD, an associate professor of endocrinology at the University of Michigan. It can be injected subcutaneously into the abdomen, thigh, or upper arm. It is crucial not to inject the medication into a muscle or vein or mix insulin and Ozempic in the same injection. Patients should also rotate their injection sites with each dose.

The dosage of Ozempic depends on the patient's needs. For those using it for type 2 diabetes and lowering the risk of heart attack or stroke, an initial dose of 0.25 milligrams (mg) is injected once a week for four weeks, followed by an increase to 0.5 mg. Healthcare providers may adjust the dose as needed, but it is essential to consult with them before making any changes independently.

Ozempic Side Effects:

Common side effects of Ozempic include nausea, vomiting, and diarrhea. Dehydration can also be a risk due to reduced food intake and gastrointestinal symptoms. Constipation may occur as the drug slows down the digestive system. Rare but severe side effects include thyroid tumors (only seen in animal studies), gallbladder problems, and kidney issues. Pancreatitis is another potential risk, although recent data has shown that this risk is minimal.

Tirzepatide (Mounjaro) is a medication developed by Eli Lilly for the management of type 2 diabetes, in conjunction with diet and exercise. Although it shares a similar function with Ozempic and Wegovy, Mounjaro exhibits some distinct characteristics:

Unique Mechanism: Mounjaro is the first drug of its kind that targets two major hormones, GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), which regulate blood sugar levels and promote weight loss.

Market Presence: As the newest drug in its class, Mounjaro has an additional compound to enhance its effects.

FDA Approval: Mounjaro was approved by the FDA for type 2 diabetes treatment in May 2022. Though not yet approved for weight loss, it may be used off-label for obesity and is expected to receive approval soon.

Mode of Action: Mounjaro works by lowering blood sugar levels, increasing insulin sensitivity, slowing digestion, and reducing appetite, leading to weight loss. Its dual hormone targeting may result in greater weight loss.

Administration: Mounjaro is a once-weekly injection that can be used alongside insulin, but it should not be mixed with insulin in the same injection. The drug is typically initiated at a weekly 2.5 mg dose and injected subcutaneously in the abdomen, thighs, or back of the upper arm.

Side Effects: Common side effects of Mounjaro include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach pain. Rarer, but more serious side effects, are pancreatitis, low blood sugar, kidney failure, allergic reactions, and gallbladder problems. The medication may also cause thyroid tumors, and patients with a family history of medullary thyroid carcinoma should avoid using it.

However the importance of using Mounjaro under the guidance of a licensed medical physician who understands the risks and benefits, as these powerful medications can have significant side effects. However, for suitable patients, Mounjaro can be a game-changer in managing their chronic medical condition, obesity.

WeGovy, Ozempic, and Mounjaro represent a new generation of medications with great promise in managing diabetes and promoting weight loss. Each medication offers unique benefits and mechanisms of action, so it's crucial to understand their differences to make the best decision for your health and well-being. If you're considering embarking on a weight loss journey or need help managing your diabetes, don't wait any longer. Take control of your health today by booking an appointment with our expert team at Beyond Healthy MD. We're here to guide and support you every step of the way, providing personalized solutions tailored to your needs. Schedule your consultation now and start transforming your life for the better.